Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat

JAMA Dermatol. 2022 Jan 1;158(1):105-107. doi: 10.1001/jamadermatol.2021.4549.

Abstract

This case series study examines the use of the histone deacetylase inhibitor remetinostat in treating patients with squamous cell carcinoma.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Squamous Cell* / drug therapy
  • Cell Line, Tumor
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Molecular Targeted Therapy
  • Skin Neoplasms* / drug therapy

Substances

  • Histone Deacetylase Inhibitors